Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2022 07:30 ET | Source: Veru Inc.

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...
July 12, 2022 16:30 ET | Source: Veru Inc.

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MIAMI, July 12, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...
July 06, 2022 07:30 ET | Source: Veru Inc.

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant and Clinically Meaningful 55.2% Reduction in Deaths...
June 24, 2022 16:30 ET | Source: Veru Inc.

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

MIAMI, June 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...
June 07, 2022 06:30 ET | Source: Veru Inc.

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

-- The EUA Submission Follows Positive Phase 3 COVID-19 Clinical Trial in which Sabizabulin Demonstrated a 55.2% Reduction in Death in Hospitalized COVID-19 Patients -- -- The Company is in...
June 06, 2022 06:30 ET | Source: Veru Inc.

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

MIAMI, June 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for...
May 31, 2022 08:30 ET | Source: Veru Inc.

Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7

MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
May 25, 2022 08:30 ET | Source: Veru Inc.

Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022

MIAMI, May 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
May 18, 2022 08:30 ET | Source: Veru Inc.

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...
May 17, 2022 08:30 ET | Source: Veru Inc.

Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022

MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right